Last reviewed · How we verify
NCT04392128: HYACINTHE
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
Phase 2 trial testing Hydroxychloroquine Sulfate 200 MG [Plaquenil] in COVID19. Withdrawn.
2 September 2020
Quick facts
| Lead sponsor | Institut de cancérologie Strasbourg Europe |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Start date | 2 September 2020 |
| Primary completion | 2 September 2020 |
| Estimated completion | 2 September 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- Hydroxychloroquine Sulfate 200 MG [Plaquenil] — full drug profile →
- Azithromycin 250 MG Oral Capsule
- Placebo oral tablet — full drug profile →
- Placebo oral capsule
Conditions studied
- COVID19 — all drugs for COVID19 →
- Hematologic Malignancy — all drugs for Hematologic Malignancy →
Sponsor
Institut de cancérologie Strasbourg Europe — full company profile →
Who can join
18 and older, any sex, with COVID19 or Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among patients with COVID-19 and hematological malignancies.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
COVID-19: Characteristics and Therapeutics.
Chilamakuri R, Agarwal S. · · 2021 · cited 192× · PMID 33494237 · DOI 10.3390/cells10020206 -
Chloroquine against malaria, cancers and viral diseases.
Zhou W, Wang H, Yang Y, Chen ZS, et al · · 2020 · cited 85× · PMID 32947043 · DOI 10.1016/j.drudis.2020.09.010 -
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Vivarelli S, Falzone L, Grillo CM, Scandurra G, et al · · 2020 · cited 63× · PMID 32785162 · DOI 10.3390/cancers12082237 -
Antibiotics for the treatment of COVID-19.
Popp M, Stegemann M, Riemer M, Metzendorf MI, et al · · 2021 · cited 60× · PMID 34679203 · DOI 10.1002/14651858.cd015025 -
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
Homolak J, Kodvanj I. · · 2020 · cited 54× · PMID 32522674 · DOI 10.1016/j.ijantimicag.2020.106044 -
Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review.
Mathioudakis AG, Fally M, Hashad R, Kouta A, et al · · 2020 · cited 14× · PMID 33333777 · DOI 10.3390/life10120350 -
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment.
Zou H, Yang Y, Dai H, Xiong Y, et al · · 2021 · cited 12× · PMID 34880750 · DOI 10.3389/fphar.2021.732403 -
Global Effect of COVID-19 Pandemic on Cancer Patients and its Treatment: A Systematic Review.
Ali M, Wani SUD, Masoodi MH, Khan NA, et al · · 2022 · cited 9× · PMID 36377228 · DOI 10.1016/j.ccmp.2022.100041
Verify or expand the search:
- PubMed search for NCT04392128
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hydroxychloroquine Sulfate 200 MG [Plaquenil]
Trials testing the same drug.
- NCT04384380 — Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19 · NA · completed
Other recruiting trials for COVID19
Currently open trials in the same condition.
- NCT07337382 — The Optimising Isolation, Quarantine and Distancing Study for COVID-19 · active not recruiting
- NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
- NCT04367883 — Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection · recruiting
Other Institut de cancérologie Strasbourg Europe trials
Trials by the same sponsor.
- NCT06476704 — Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas · Phase 2 · not yet recruiting
- NCT06477939 — Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomi · Phase 3 · not yet recruiting
- NCT06458517 — Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Muco · NA · not yet recruiting
- NCT06775119 — Feasibility Study of a Neuromuscular Fatigue Test and Associated Hemodynamic Responses: Application in Healthy Volunteer · NA · completed
- NCT06536556 — Effects of a Single Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: Comparison of Paclitaxel v · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04392128 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut de cancérologie Strasbourg Europe
- Last refreshed: 4 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04392128.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing